Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 4/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | DRD2 | P14416 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | SPTLC2 | O15270 | 6/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4149659 | 1.00 | F2R (0.48) | F2RDRD4DRD2EPHX2TEAD1 | |
| SCHEMBL4147621 | 0.94 | MGLL (0.49) | F2RDRD4DRD2EPHX2SPTLC2 | |
| SCHEMBL4147623 | 0.94 | MGLL (0.49) | F2RDRD4DRD2EPHX2SPTLC2 | |
| SCHEMBL4148957 | 0.90 | F2R (0.47) | F2RDRD4DRD2EPHX2MAOA | |
| SCHEMBL4148954 | 0.90 | F2R (0.47) | F2RDRD4DRD2EPHX2MAOA | |
| SCHEMBL4153226 | 0.90 | TACR2 (0.51) | F2RDRD4DRD2SPTLC2 | |
| SCHEMBL4141820 | 0.87 | KCNH2 (0.46) | — | |
| SCHEMBL4141816 | 0.87 | KCNH2 (0.46) | — | |
| SCHEMBL4153321 | 0.86 | SPTLC2 (0.48) | F2REPHX2SPTLC2 | |
| SCHEMBL4162645 | 0.86 | SPTLC2 (0.41) | F2RMAOASPTLC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8470816-B2 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-06-25 | — | — | US | disclosed |
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156572-A1 | Nitrogen-containing heterocyclic compound and use thereof | NTSR2, NTSR1, HNMT | F2R 298/4885DRD4 852/4885DRD2 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.